About this trial
Our study hypothesizes that fluorescein exposure in diabetic patients with advanced chronic kidney disease results in deterioration of kidney function. It will therefore aim to evaluate the incidence of acute kidney injury induced by fluorescein in diabetic patients with CKD. The objective is to determine the incidence, severity and risk factors associated with this deterioration to improve the care of this specific population.
Eligibility criteria
Qualifiers
>18 years old with type 2 or type 1 diabetes and chronic kidney disease stage 3b to 5 (eGFR<45 mL/min/1.73 m2)
Disqualifiers
Patients who do not give their consent
Patients who are allergic to fluorescein
Patients who are on dialysis
Patients who had fever, vomiting, diarrhea or any dehydration 48 hours before the intervention
Trial design
Treatments tested in this trial
- Fluorescein angiography
Treatment groups
Locations
1Sponsors and collaborators
Saint-Joseph University
Lead sponsor